HSCS Key Statistics, Chart & Performance
The current stock price of HSCS is 3.1 USD. In the past month the price increased by 16.67%. In the past year, price decreased by -9.41%.
HSCS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.77 | 223.61B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.46 | 208.95B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.94 | 144.07B | ||
| SYK | STRYKER CORP | 27.4 | 138.02B | ||
| BDX | BECTON DICKINSON AND CO | 14.13 | 58.17B | ||
| IDXX | IDEXX LABORATORIES INC | 55.22 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.48 | 49.93B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.88 | 39.48B | ||
| RMD | RESMED INC | 25.11 | 36.29B | ||
| DXCM | DEXCOM INC | 37.52 | 27.22B | ||
| PODD | INSULET CORP | 63.77 | 20.50B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.64 | 18.66B |
Related stock screener links
About HSCS
Company Profile
HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 15 full-time employees. The company went IPO on 2022-06-15. The firm has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The company delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Company Info
HEARTSCIENCES INC
550 Reserve St, Suite 360
Southlake TEXAS US
Employees: 15
Phone: 16822377781
HEARTSCIENCES INC / HSCS FAQ
What does HSCS do?
HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 15 full-time employees. The company went IPO on 2022-06-15. The firm has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The company delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Can you provide the latest stock price for HEARTSCIENCES INC?
The current stock price of HSCS is 3.1 USD. The price increased by 0.65% in the last trading session.
Does HSCS stock pay dividends?
HSCS does not pay a dividend.
How is the ChartMill rating for HEARTSCIENCES INC?
HSCS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for HEARTSCIENCES INC?
HEARTSCIENCES INC (HSCS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the market cap for HEARTSCIENCES INC?
HEARTSCIENCES INC (HSCS) has a market capitalization of 9.52M USD. This makes HSCS a Nano Cap stock.
HSCS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HSCS. When comparing the yearly performance of all stocks, HSCS is a bad performer in the overall market: 79.98% of all stocks are doing better.
HSCS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HSCS. While HSCS seems to be doing ok healthwise, there are quite some concerns on its profitability.
HSCS Financial Highlights
Over the last trailing twelve months HSCS reported a non-GAAP Earnings per Share(EPS) of -6.88. The EPS increased by 74.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.22% | ||
| ROE | -279.15% | ||
| Debt/Equity | 0 |
HSCS Forecast & Estimates
8 analysts have analysed HSCS and the average price target is 13.77 USD. This implies a price increase of 344.19% is expected in the next year compared to the current price of 3.1.